Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
SCN1A 6323 ZONISAMIDE CHEMBL750 inhibitor, blocker TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 19557119, 20025128, 11752352, 20001433, 18433351, 14704463, 15511691, 19948168
SCN1A 6323 PHENACEMIDE CHEMBL918 inhibitor, blocker TdgClinicalTrial, ChemblInteractions, TEND, DrugBank, TTD 11752352, 17139284, 17016423, 3959032
SCN1A 6323 PHENAZOPYRIDINE HYDROCHLORIDE CHEMBL1201022 inhibitor, blocker ChemblInteractions, DrugBank 20976818, 8799190
SCN1A 6323 PERMETHRIN CHEMBL1525 inhibitor DrugBank 14651650, 19171193, 19960691, 19766671, 20881019
SCN1A 6323 CHEMBL270497 CHEMBL270497 gating inhibitor GuideToPharmacologyInteractions
SCN1A 6323 LAMOTRIGINE CHEMBL741 blocker PharmGKB, ChemblInteractions
SCN1A 6323 BENOXINATE HYDROCHLORIDE CHEMBL1200654 blocker ChemblInteractions
SCN1A 6323 MEXILETINE HYDROCHLORIDE CHEMBL1200606 blocker ChemblInteractions
SCN1A 6323 PHENYTOIN SODIUM CHEMBL1611 blocker ChemblInteractions
SCN1A 6323 ETIDOCAINE HYDROCHLORIDE CHEMBL1200597 blocker ChemblInteractions
SCN1A 6323 ORPHENADRINE CITRATE CHEMBL1200395 blocker ChemblInteractions
SCN1A 6323 INDECAINIDE HYDROCHLORIDE CHEMBL1200341 blocker ChemblInteractions
SCN1A 6323 ETHOTOIN CHEMBL1095 blocker ChemblInteractions
SCN1A 6323 ROPIVACAINE HYDROCHLORIDE CHEMBL1889140 blocker ChemblInteractions
SCN1A 6323 FOSPHENYTOIN SODIUM CHEMBL919 blocker ChemblInteractions
SCN1A 6323 SAXITOXIN CHEMBL501134 channel blocker GuideToPharmacologyInteractions
SCN1A 6323 CHLOROPROCAINE HYDROCHLORIDE CHEMBL944 blocker ChemblInteractions
SCN1A 6323 HEXYLCAINE HYDROCHLORIDE CHEMBL1200715 blocker ChemblInteractions
SCN1A 6323 DYCLONINE HYDROCHLORIDE CHEMBL1200478 blocker ChemblInteractions
SCN1A 6323 LIDOCAINE HYDROCHLORIDE HYDRATE CHEMBL1200409 blocker ChemblInteractions
SCN1A 6323 TETRACAINE HYDROCHLORIDE CHEMBL1255654 blocker ChemblInteractions
SCN1A 6323 ESLICARBAZEPINE CHEMBL315985 blocker ChemblInteractions
SCN1A 6323 QUINIDINE POLYGALACTURONATE CHEMBL1201486 blocker ChemblInteractions
SCN1A 6323 PROPAFENONE HYDROCHLORIDE CHEMBL1201063 blocker ChemblInteractions
SCN1A 6323 ESLICARBAZEPINE ACETATE CHEMBL87992 blocker ChemblInteractions
SCN1A 6323 ARTICAINE HYDROCHLORIDE CHEMBL1200819 blocker ChemblInteractions
SCN1A 6323 PROPOXYCAINE HYDROCHLORIDE CHEMBL1769 blocker ChemblInteractions
SCN1A 6323 OXCARBAZEPINE CHEMBL1068 blocker ChemblInteractions
SCN1A 6323 TOPIRAMATE CHEMBL220492 inhibitor, blocker TdgClinicalTrial, ChemblInteractions, TEND, DrugBank 17621480, 15526956, 11948006, 12861512, 15508261
SCN1A 6323 VERATRIDINE CHEMBL439496 activator GuideToPharmacologyInteractions
SCN1A 6323 PHENYTOIN CHEMBL16 blocker TdgClinicalTrial, ChemblInteractions, TEND
SCN1A 6323 SAFINAMIDE CHEMBL396778 TdgClinicalTrial
SCN1A 6323 NW-3509 CHEMBL3545207 blocker ChemblInteractions
SCN1A 6323 RILUZOLE CHEMBL744 blocker ChemblInteractions
SCN1A 6323 PRIMIDONE CHEMBL856 blocker ChemblInteractions
SCN1A 6323 DRONEDARONE HYDROCHLORIDE CHEMBL1201729 blocker ChemblInteractions
SCN1A 6323 MERETHOXYLLINE PROCAINE CHEMBL1200443 blocker ChemblInteractions
SCN1A 6323 CARBAMAZEPINE CHEMBL108 blocker ChemblInteractions
SCN1A 6323 LIDOCAINE CHEMBL79 blocker ChemblInteractions
SCN1A 6323 PROPARACAINE HYDROCHLORIDE CHEMBL1200464 blocker ChemblInteractions
SCN1A 6323 DISOPYRAMIDE PHOSPHATE CHEMBL1201020 blocker ChemblInteractions
SCN1A 6323 PROCAINE HYDROCHLORIDE CHEMBL1200841 blocker ChemblInteractions
SCN1A 6323 QUINIDINE GLUCONATE CHEMBL1200437 blocker ChemblInteractions
SCN1A 6323 LACOSAMIDE CHEMBL58323 blocker ChemblInteractions
SCN1A 6323 NITRAZEPAM CHEMBL13209 TdgClinicalTrial, TEND, DrugBank 2450203
SCN1A 6323 LEVETIRACETAM CHEMBL1286 blocker TTD
SCN1A 6323 QUINIDINE SULFATE CHEMBL3707183 blocker ChemblInteractions
SCN1A 6323 MEPHENYTOIN CHEMBL861 blocker ChemblInteractions
SCN1A 6323 ORPHENADRINE (CHLORIDE) CHEMBL1201023 blocker ChemblInteractions
SCN1A 6323 RUFINAMIDE CHEMBL1201754 blocker ChemblInteractions
SCN1A 6323 PRILOCAINE HYDROCHLORIDE CHEMBL1200586 blocker ChemblInteractions
SCN1A 6323 TOCAINIDE HYDROCHLORIDE CHEMBL1200773 blocker ChemblInteractions
SCN1A 6323 IRAMPANEL CHEMBL29741 blocker ChemblInteractions
SCN1A 6323 NERISPIRDINE CHEMBL2107762 blocker ChemblInteractions
SCN1A 6323 RALFINAMIDE CHEMBL2107771 blocker ChemblInteractions
SCN1A 6323 MORICIZINE HYDROCHLORIDE CHEMBL1200334 blocker ChemblInteractions
SCN1A 6323 PROCAINAMIDE HYDROCHLORIDE CHEMBL605 blocker ChemblInteractions
SCN1A 6323 NKTR-171 CHEMBL3545209 blocker ChemblInteractions
SCN1A 6323 PRILOCAINE CHEMBL1194 blocker ChemblInteractions
SCN1A 6323 TETRACAINE CHEMBL698 blocker ChemblInteractions
SCN1A 6323 MEPIVACAINE HYDROCHLORIDE CHEMBL1200440 blocker ChemblInteractions
SCN1A 6323 DRONEDARONE CHEMBL184412 inhibitor DrugBank 12890054
SCN1A 6323 TETRODOTOXIN CHEMBL507974 channel blocker TdgClinicalTrial, GuideToPharmacologyInteractions, DrugBank 17663442

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
SCN1A rs3812718 T phenytoin efficacy no No significant association between the variant and the number of patients with drug-resistant epilepsy. Please note that alleles have been complemented to the positive strand. Allele T is not associated with resistance to phenytoin in people with Epilepsy as compared to allele C. 32457604 1451151724
SCN1A rs3812718 TT carbamazepine dosage yes Only patients who completed the full 12 months of carbamazepine therapy (i.e. the retention cohort) were included. Patients with the TT genotype had a higher maintenance dose and higher serum levels compared to those with the GG genotype. Please note alleles have been complemented to the positive chromosomal strand. Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC. 22292851 981500472
SCN1A rs3812718 TT carbamazepine metabolism/PK yes The authors evaluated daily dose and maintenance dose and calculated the means for each genotype. The TT genotype is associated with a higher mean daily dose and higher mean maintenance dose of carbamazepine (CBZ). Mean CBZ daily dose (mg/day) for the TT genotype was 694 vs. 509-531 for the CT and CC genotypes, respectively. Mean CBZ maintenance dose for the TT genotype was 10.48 versus 7.79-7.96 for the CC and CT genotypes, respectively. Please note: alleles have been complemented to the + chromosomal strand. Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT. 26555147 1447678164
SCN1A rs3812718 TT carbamazepine efficacy yes The TT genotype was more frequent in the drug resistant patients treated with carbamazepine/oxcarbamazepine monotherapy. The TC genotype was not found at a statistically higher frequency in patients with drug resistance. Alleles have been complemented to the plus chromosomal strand. Variant described as SCN1A IVS5-91G>A. Remained significant after Bonferroni correction of p<0.041. Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC. 25155934 1184999651
SCN1A rs2298771 C carbamazepine efficacy yes All patients included in this study were receiving antiepileptic treatment as either mono or polytherapy. Allele C is associated with increased response to carbamazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, oxcarbazepine or valproic acid in children with Epilepsy as compared to allele T. 28753467 1448821318
SCN1A rs3812718 T carbamazepine efficacy no No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction. Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C. 23859570 1183611749
SCN1A rs3812718 T carbamazepine efficacy no No significant association was found with this SNP and response to epilepsy drugs. Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C. 23859570 1183606890
SCN1A rs3812718 TT carbamazepine dosage yes Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC. 15805193 613978592
SCN1A rs2298771 C carbamazepine "dosage","metabolism/PK" no and not associated with In concentration/dose ratio. Allele C is not associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T. 22188362 827824050
SCN1A rs2298771 TT carbamazepine efficacy yes Patients with the TT genotype were more likely to have a "good" response to carbamazepine. A "good" response was classified as seizure free over 24 months of treatment. A "bad" response was classified as anything other than seizure free. This significant result was only seen for months 3-15 of treatment. No significant result was seen for months 15-24 months of treatment. Please note alleles have been complemented to the plus chromosomal strand. Genotype TT is associated with increased response to carbamazepine in people with Epilepsy as compared to genotypes CC + CT. 22591328 982023314
SCN1A rs2298771 T carbamazepine efficacy no No significant association was found with this SNP and response to epilepsy drugs. Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C. 23859570 1183612568
SCN1A rs3812718 TT carbamazepine "dosage","metabolism/PK" yes and decreased In concentration/dose ratio. Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CC + CT. 22188362 827823984
SCN1A rs2298771 CC carbamazepine efficacy no Genotypes of this SNP did not have significantly different frequencies in the drug resistant patients compared to drug responsive patients. Alleles have been complemented to the plus chromosomal strand. Variant described as SCN1A c.3184A>G. Genotype CC is not associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype TT. 25155934 1184999830
SCN1A rs2298771 TT carbamazepine metabolism/PK no The authors evaluated the distribution of genotypes between individuals who developed resistance to carbamazepine (CBZ) and those who did not. There were no significant differences in genotype distributions between the two groups. Please note: alleles have been complemented to the + chromosomal strand. Genotype TT is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CC + CT. 26555147 1447678461
SCN1A rs3812718 CC carbamazepine efficacy no The authors evaluated the distribution of genotypes between individuals who developed resistance to carbamazepine (CBZ) and those who did not. There were no significant differences in genotype distributions between the two groups. Please note: alleles have been complemented to the + chromosomal strand. Genotype CC is not associated with resistance to carbamazepine in people with Epilepsy as compared to genotypes CT + TT. 26555147 1447678481
SCN1A rs2298771 CC carbamazepine metabolism/PK no In none of the measures that the authors used to measure exposure showed any association with the genotype. Please note: alleles have been complemented to the + chromosomal strand. Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. 26555147 1447678311
SCN1A rs3812718 CT + TT carbamazepine "dosage","metabolism/PK" no This was not significant after bonferroni correction. This SNP was also associated with concentration dose ratio in multivariate analysis but was not significantly associated with metabolite CBZ 10,11-epoxide (CBZE) concentration. Genotypes CT + TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC. 26314341 1447678392
SCN1A rs3812718 T oxcarbazepine dosage no but did not remain significant after Bonferroni correction for multiple testing. Allele T is associated with increased dose of oxcarbazepine in people with Epilepsy as compared to allele C. 25823783 1447944930
SCN1A rs3812718 CT carbamazepine "dosage","metabolism/PK" yes and decreased In concentration/dose ratio. Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC. 22188362 827823998
SCN1A rs3812718 T phenytoin dosage yes Allele T is associated with increased dose of phenytoin in people with Epilepsy as compared to allele C. 15805193 613978601
SCN1A rs3812718 CT + TT phenytoin dosage no Reported as for SCN1A IVS5-91 G>A. Not significant after correction for multiple testing. Genotypes CT + TT are associated with increased dose of phenytoin in people with Epilepsy as compared to genotype CC. 17001291 769248943
SCN1A rs3812718 C carbamazepine "dosage","efficacy" no "Case/Control" numbers are for drug-responsive vs. drug-resistant patients. More patients were taking carbamazepine than oxcarbazepine, and these groups were pooled for analysis. Allele C is not associated with response to carbamazepine or oxcarbazepine in people with Epilepsy as compared to allele T. 21561445 981478948
SCN1A rs3812718 CC + CT carbamazepine efficacy yes Patients with the CC and CT genotypes have increased tolerability to carbamazepine. Tolerability was assessed by retention rates, or the proportion of patients that continued to take carbamazepine for seizures over the preceding 3 months. Patients were assessed every 3 months for 24 months. The retention rates for the CC + CT genotypes were significantly greater than the retention rate for the TT genotype during months 9 - 15 of treatment. Please note alleles have been complemented to the plus chromosomal strand. Genotypes CC + CT are associated with increased response to carbamazepine in people with Epilepsy as compared to genotype TT. 22591328 982023280
SCN1A rs3812718 TT carbamazepine dosage yes Patients with the TT genotype have increased maintenance dose and serum levels of carbamazepine between 3 and 12 months of treatment. No significant difference between genotypes was seen between 15 and 24 months of treatment. Please note alleles have been complemented to the plus chromosomal strand. Genotype TT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype CC. 22591328 982023304
SCN1A rs3812718 TT carbamazepine efficacy yes The TT genotype was more frequent in the drug resistant patients. The TC genotype was not found at a statistically higher frequency in patients with drug resistance. Alleles have been complemented to the plus chromosomal strand. Variant described as SCN1A IVS5-91G>A. Remained significant after Bonferroni correction of p<0.041. Genotype TT is associated with resistance to carbamazepine or oxcarbazepine in people with Epilepsy as compared to genotype CC. 25155934 1184999606
SCN1A rs3812718 TT carbamazepine metabolism/PK yes The authors evaluated maintenance dose-adjusted concentrations of carbamazepine (CBZ), its active metabolite, CBZ-epoxide (CBZE), and its inactive metabolite CBZ-diol (CBZD) as well as CBZE:CBZ, CBZD:CBZ and CBZD:CBZE ratios. The TT genotype is associated with a lower mean dose adj. concentration of CBZ (microgram/mL per mg/Kg) (0.71 for the TT genotype vs. 0.92-1.11 for the CT and CC genotypes, respectively) as well as a higher mean CBZD:CBZ (0.43 for TT vs. 0.23-0.27 for the CT and CC genotypes, respectively). Please note: alleles have been complemented to the + chromosomal strand. Genotype TT is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT. 26555147 1447678220
SCN1A rs10188577 CT antiepileptics efficacy yes When correcting for age of onset, seizure type and aetiology, those who were heterozygotes were more likely to be drug-resistant. Drug resistance defined as the occurrence of at least four seizures over a year with trials of two or more sodium channel blocking antiepileptics and maximal tolerated doses. Genotype CT is associated with increased resistance to antiepileptics in people with Epilepsy. 24342961 1184747623
SCN1A rs2298771 T carbamazepine efficacy no No significant association was found with this SNP and response to epilepsy drugs after 1000 permutation testing for each marker or haplotype and Bonferroni correction. Variant described as Thr1067Ala A>G therefore minor allele taken as G (here alleles are complemented for the plus chromosomal strand T>C). Allele T is not associated with response to carbamazepine or valproic acid in people with Epilepsy as compared to allele C. 23859570 1183612769
SCN1A rs2298771 CC carbamazepine metabolism/PK no There was no association between dose (mean daily, or mean maintenance) with the genotype. Please note: alleles have been complemented to the + chromosomal strand. Genotype CC is not associated with dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. 26555147 1447678320